Last reviewed · How we verify

Thiazide or Thiazide-like diuretics

National University of Ireland, Galway, Ireland · FDA-approved active Small molecule

Thiazide and thiazide-like diuretics inhibit sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary sodium and water excretion to reduce blood volume and blood pressure.

Thiazide and thiazide-like diuretics inhibit sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary sodium and water excretion to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis.

At a glance

Generic nameThiazide or Thiazide-like diuretics
Also known asHydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide
SponsorNational University of Ireland, Galway, Ireland
Drug classThiazide diuretic
TargetSodium-chloride cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

These drugs block the sodium-chloride cotransporter (NCC) in the kidney's distal convoluted tubule, preventing electrolyte reabsorption and increasing urine output. By reducing circulating blood volume and total body sodium, they lower blood pressure. They also have a direct vasodilatory effect on blood vessels that contributes to their antihypertensive action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: